Jazz Pharmaceuticals

Gut stomach
Biotech

ESMO: Jazz HER2 bispecific posts 59% survival at 30 months

The 30-month data unveiled at ESMO gave other insights into zanidatamab’s efficacy, including a confirmed objective response rate of 84%.
James Waldron Sep 16, 2024 3:00am
Graphic showing arrows missing the bullseye on a target

Jazz's ph. 2 essential tremor test misses endpoint

Jun 20, 2024 9:30am
Pythagorean theorem

ASCO: It's back to the basics for cancer drug developers

Jun 5, 2024 10:55am
ASCO 2024

ASCO: Jazz shares 'unprecedented' biliary tract cancer data

Jun 1, 2024 11:11am
Photo of a parachutes opened with a dark blue sky in the background

John Cox gets new biotech CEO gig at Dyne—Chutes & Ladders

Mar 29, 2024 9:30am
deal handshake business cooperation partnerships

Jazz jumps into KRAS G12D space via $10M upfront deal with Redx

Feb 7, 2024 8:30am